A reappraisal of the effects of adenosine 3':5'-cyclic monophosphate on the function and morphology of the rat prostate gland.
1. A comparison was made of the binding of 5alpha-dihydrotestosterone (17beta-hydroxy-5alpha-androstan-3-one) and cyclic AMP in the rat prostate gland. Distinct binding mechanisms exist for these compounds, and cyclic AMP cannot serve as a competitor for the 5alpha-dihydrotestosterone-binding sites and vice versa. In contrast with the results obtained with 5alpha-dihydrotestosterone, very small amounts of cyclic AMP are retained in nuclear chromatin and the overall binding of this cyclic nucleotide is not markedly affected by castration. 2. Androgenic stimulation does not lead to major increases in the adenylate cyclase activities associated with any subcellular fraction of the prostate gland. Accordingly, changes in the concentration of cyclic AMP in the prostate gland after hormonal treatment are likely to be small, but these were not measured directly. 3. When administered to whole animals in vivo, small amounts of non-degraded cyclic AMP are found in the prostate gland but sufficient to promote an activation of certain carbohydrate-metabolizing enzymes in the cell supernatant fraction. The stimulatory effects of cyclic AMP were not evident with cytoplasmic enzymes engaged in polyamine synthesis or nuclear RNA polymerases. These latter enzymes were stimulated solely by the administration of testosterone. 4. By making use of antiandrogens, a distinction can be drawn between the biochemical responses attributable to the binding of 5alpha-dihydrotestosterone but not of cyclic AMP. Evidence is presented to suggest that the stimulation of RNA polymerase, ornithine decarboxylase and S-adenosyl-l-methionine decarboxylase is a consequence of the selective binding of 5alpha-dihydrotestosterone. Only the stimulation of glucose 6-phosphate dehydrogenase can be attributed to cyclic AMP or other metabolites of testosterone. 5. Overall, this study indicates that the formation of cyclic AMP is not a major feature of the androgenic response and affects only a restricted number of biochemical processes. Certainly, cyclic AMP cannot be considered as interchangeable with testosterone and its metabolites in the control of the function of the prostate gland. This difference is additionally emphasized by the failure of cyclic AMP to restore the morphology of the prostate gland in castrated animals; morphological restoration only follows the administration of androgens.
D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D001665:Binding Sites; D002262:Carboxy-Lyases / Q000378:metabolism; D002369:Castration; D000242:Cyclic AMP / Q000494:pharmacology*; D003534:Cyproterone / Q000494:pharmacology; D012321:DNA-Directed RNA Polymerases / Q000378:metabolism; D013196:Dihydrotestosterone / Q000378:metabolism*; D004591:Electrophoresis, Polyacrylamide Gel; D005954:Glucosephosphate Dehydrogenase / Q000378:metabolism; D008297:Male; D009952:Ornithine; D011467:Prostate / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D011485:Protein Binding; D011700:Putrescine; D051381:Rats; D012436:S-Adenosylmethionine; D013056:Spectrophotometry, Ultraviolet; D013347:Subcellular Fractions / Q000378:metabolism; D013739:Testosterone / Q000494:pharmacology; D013997:Time Factors; D014316:Tritium
D013196:Dihydrotestosterone; D014316:Tritium; D013739:Testosterone; D012436:S-Adenosylmethionine; D000242:Cyclic AMP; D009952:Ornithine; D003534:Cyproterone; D005954:Glucosephosphate Dehydrogenase; D012321:DNA-Directed RNA Polymerases; D002262:Carboxy-Lyases; D000262:Adenylyl Cyclases; D011700:Putrescine